Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2026-01-09 00:00:00 ET · period of report 2026-01-06 · accession 0001104659-26-002501 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | 2026-01-06 | NVCT | Shemesh Shay | Chief Dev, Ops. Off | A - Grant | $0.00 | +150.0K | 1.79M | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-06 | A | A | 150,000 | $0.00 | 1,793,068 | D | — | — | (F1) The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Shemesh's continued service on such dates. (F2) Includes shares of restricted common stock. |